Table 1.

Characteristics at entry to the NSABP STAR Trial (P-2) for women included in the STAR-update analyses

Participant characteristicsTamoxifenRaloxifene
Age (years)
No. 1° relatives with breast cancer
History of hysterectomy
History of lobular carcinoma in situ
History of breast atypical hyperplasia
5-year predicted breast cancer risk (%)*

Abbreviation: NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene.

  • *Determined by the Gail model.